Get the Stockscreener App
46.88
1.94%
0.89
After Hours:
47.00
0.12
+0.26%
Soleno Therapeutics Inc stock is traded at $46.88, with a volume of 341.79K.
It is up +1.94% in the last 24 hours and down -1.62% over the past month.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
See More
Previous Close:
$45.99
Open:
$46.46
24h Volume:
341.79K
Relative Volume:
0.58
Market Cap:
$2.02B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-15.64
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+8.75%
1M Performance:
-1.62%
6M Performance:
-3.70%
1Y Performance:
+4.36%
1-Day Range:
$45.44
$47.82
1-Week Range:
$41.50
$49.03
52-Week Range:
$36.61
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
46.88 | 2.02B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics Breaks Above 200-Day Moving AverageBullish for SLNO - Nasdaq
Soleno Therapeutics (NASDAQ:SLNO) Trading 8.6% HigherHere's What Happened - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $74.83 Consensus PT from Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential? - MSN
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
Analysts Predict How High Soleno Therapeutics Inc (SLNO) Will Go. - Stocks Register
Have Insiders Sold Soleno Therapeutics Shares Recently? - Simply Wall St
Trading (SLNO) With Integrated Risk Controls - Stock Traders Daily
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven? - Yahoo Finance
Soleno Therapeutics senior VP Patricia Hirano sells $138,709 in stock By Investing.com - Investing.com Australia
Soleno therapeutics' SVP Kristen Yen sells $222,483 in stock By Investing.com - Investing.com Australia
Soleno Therapeutics CFO James Mackaness sells $360,460 in stock By Investing.com - Investing.com South Africa
Soleno Therapeutics CFO James Mackaness sells $360,460 in stock - Investing.com India
Soleno Therapeutics CEO sells $965,515 in stock - Investing.com India
Soleno therapeutics’ SVP Kristen Yen sells $222,483 in stock By Investing.com - Investing.com Nigeria
Soleno Therapeutics CEO sells $965,515 in stock By Investing.com - Investing.com South Africa
Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Sells 10,937 Shares of Stock - MarketBeat
Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) CFO Sells 4,083 Shares of Stock - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $108,061.20 in Stock - MarketBeat
Soleno Therapeutics senior VP Patricia Hirano sells $138,709 in stock - Investing.com India
Soleno therapeutics' SVP Kristen Yen sells $222,483 in stock - Investing.com India
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 2.5%Time to Sell? - MarketBeat
Soleno Therapeutics, Inc.'s (NASDAQ:SLNO) Path To Profitability - Simply Wall St
Investors Buy Large Volume of Soleno Therapeutics Put Options (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Target of Unusually High Options Trading (NASDAQ:SLNO) - MarketBeat
(SLNO) Long Term Investment Analysis - Stock Traders Daily
Geode Capital Management LLC Buys 51,189 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Barclays PLC Acquires 31,467 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Soleno Therapeutics is Now Oversold (SLNO) - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.11 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Teachers Retirement System of The State of Kentucky Buys Shares of 13,001 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
State Street Corp Has $57.67 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
State Street Corp Buys 142,033 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewswire
Soleno Therapeutics Secures Massive $200M Financing Deal for Rare Disease Drug Development - StockTitan
When (SLNO) Moves Investors should Listen - Stock Traders Daily
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) & Pixie Dust Technologies (NASDAQ:PXDT) Head to Head Survey - Defense World
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape By Investing.com - Investing.com South Africa
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape - Investing.com
Wellington Management Group LLP Acquires 290,135 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
FDA delays approval decision until March on DCCR for excessive hunger in PWS - Prader-Willi Syndrome News
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):